» Articles » PMID: 38688616

Risk of Keratitis and Keratopathy in Hidradenitis Suppurativa Patients: A Global Federated Health Network Analysis

Overview
Journal In Vivo
Specialty Oncology
Date 2024 Apr 30
PMID 38688616
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aim: Hidradenitis suppurativa (HS) is linked to immune dysregulation and systemic inflammation. While previous studies indicate a higher prevalence of ocular manifestations in HS, the specific risk of keratopathy and keratitis remains unclear. The primary aim of this study was to assess the risk of keratitis and keratopathy in individuals with HS.

Patients And Methods: In this retrospective cohort study conducted with data from the TriNetX database, 53,716 patients with HS were matched to an equivalent number of non-HS controls using propensity score matching. The study covered the period from January 1st, 2005, to December 31st, 2017. Hazard ratios and their respective 95% confidence intervals (CIs), were computed to evaluate the occurrences of keratitis and keratopathy over a 5-year duration in patients with HS, compared to non-HS controls.

Results: HS was associated with a 1.52 times higher risk of keratitis over a 5-year period (95%CI=1.24-1.86) and a 1.47 times higher risk of keratopathy (95%CI=1.18-1.84). These risks remained consistent in sensitivity analyses. The elevated risk of keratitis was observed across both sexes. However, the risk of keratopathy was significantly higher in women with HS (HR=1.61, 95%CI=1.24-2.10) and individuals aged 18-64 years (HR=1.32, 95%CI=1.04-1.68).

Conclusion: HS was linked to an elevated risk of both keratitis and keratopathy over a 5-year period. Ophthalmologic manifestations are recommended to be considered in HS standard care.

Citing Articles

Renal dysfunction in people with hidradenitis suppurativa: a multi-center, propensity-score-matched cohort study.

Gau S, Yang C, Li Y, Lee C, Su Y, Chang H Int J Med Sci. 2025; 22(3):558-564.

PMID: 39898256 PMC: 11783075. DOI: 10.7150/ijms.102434.


Risk of Upper Limb Diseases in Osteoarthritis Patients: A Propensity-score-matched Cohort Study.

Su Y, Gau S In Vivo. 2024; 38(5):2464-2470.

PMID: 39187330 PMC: 11363754. DOI: 10.21873/invivo.13716.


Thyroid Diseases After Total Knee Replacement: A Multi-center, Propensity-score-matched Cohort Study.

Li C, Lo S, Hsu C, Li Y, Tsai R, Chang H In Vivo. 2024; 38(5):2446-2454.

PMID: 39187324 PMC: 11363761. DOI: 10.21873/invivo.13714.


New-Onset Hidradenitis Suppurativa in Psoriasis Patients: A Multi-Center, Retrospective Cohort Study.

Li C, Lo S, Tsai R, Chang H, Gau S Life (Basel). 2024; 14(6).

PMID: 38929713 PMC: 11205059. DOI: 10.3390/life14060730.

References
1.
Kelly G, Hughes R, McGarry T, van den Born M, Adamzik K, FitzGerald R . Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol. 2015; 173(6):1431-9. DOI: 10.1111/bjd.14075. View

2.
Gargallo-Benedicto A, Clemente-Tomas R, Pastor-Espuig M, Ballano-Ruiz A, Garzaran-Teijeiro A, Alias-Alegre E . Bilateral Phlyctenular Keratoconjunctivitis in the Context of Hidradenitis Suppurativa: A Case Report and Literature Review. Ocul Immunol Inflamm. 2020; 30(4):992-994. DOI: 10.1080/09273948.2020.1833223. View

3.
van der Zee H, Laman J, Boer J, Prens E . Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol. 2012; 21(10):735-9. DOI: 10.1111/j.1600-0625.2012.01552.x. View

4.
Messmer E . The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015; 112(5):71-81. PMC: 4335585. DOI: 10.3238/arztebl.2015.0071. View

5.
Alzaga Fernandez A, Demirci H, Darnley-Fisch D, Steen D . Interstitial keratitis secondary to severe hidradenitis suppurativa: a case report and literature review. Cornea. 2010; 29(10):1189-91. DOI: 10.1097/ICO.0b013e3181d4fd5c. View